Skip to main content

Table 2 Clinical and ultrasound parameters at baseline and after 12 months in total population, group of responders and non-responders

From: Fluorescence optical imaging for treatment monitoring in patients with early and active rheumatoid arthritis in a 1-year follow-up period

  Month of visit 0 (V0)* Month of visit 12 (V12)* Difference between V12 and V0* p value (Wilcoxon signed rank test)
Total population (n = 35 for clinical, n = 34 for US7 parameters)
 28-SJC 5 (3;9.5)
(1;20)
1 (0;2)
(0;10)
−4 (−7;− 1)
(−19;3)
< 0.001 (sig.)
 28-TJC 7 (3.5;15)
(1;25)
1 (0;3)
(0;26)
−4 (− 10;− 1)
(−24;6)
< 0.001 (sig.)
 DAS28(ESR) 5.61 (4.8;6.23)
(3.55;7.57)
3.31 (2.45;3.98)
(1.13;6.19)
−2.22 (−3.11;− 1.39)
(−5.45;0.56)
< 0.001 (sig.)
 GS-synovitis 7 (5.5;9.5)
(2;15)
6 (4.25;7)
(2;10)
− 1 (−3;0)
(−9;7)
0.0112 (sig.)
 GS-tenosynovitis 3 (2;4)
(0;5)
2.5 (2;3)
(0;4)
−0.5 (−1.75;0)
(−4;2)
0.0239 (sig.)
 PD-synovitis 4 (3;7)
(2;15)
3 (2;3.75)
(0;11)
−1 (−3;0)
(−9;1)
0.00004 (sig.)
 PD-tenosynovitis 3 (2;4)
(0;7)
2 (1.25;3)
(0;5)
0 (−2;0.75)
(−4;1)
0.0163 (sig.)
Group of responders (n = 16)
 28-SJC 3.5 (1.75;8.25)
(1;15)
0 (0;1)
(0;3)
−3.5 (−8.25;− 1) (−14;1) 0.002 (sig.)
 28-TJC 4.5 (3;10.5)
(1;24)
0 (0;0.25)
(0;2)
−3.5 (−10.5;− 3) (−24;− 1) < 0.001 (sig.)
 DAS28(ESR) 4.88 (4.33;6.18)
(3.55;7.33)
2.38 (1.89;2.68)
(1.13;3.18)
−2.82 (−3.82;− 1.82)
(−5.45;− 1.14)
< 0.001 (sig.)
 GS-synovitis 8 (6;9.25)
(2;12)
6 (4;7)
(3;9)
−2 (−4.25;0)
(−9;7)
0.038 (sig.)
 GS-tenosynovitis 4 (2.75;5)
(1;5)
2.5 (2;3)
(1;4)
−1 (−2;0)
(−4;2)
0.0274 (sig.)
 PD-synovitis 4 (3.75;6.5)
(2;11)
3 (2;3)
(1;4)
−2 (−5;− 0.75)
(−8;1)
0.0028 (sig.)
 PD-tenosynovitis 3 (2;5)
(1;7)
2 (2;3)
(1;3)
−1 (−2.25;0)
(−4;1)
0.01 (sig.)
Group of non-responders (n = 19 for clinical, n = 18 for US7 parameters)
 28-SJC 6 (3.5;9.5)
(1;20)
1 (0;4)
(0;10)
−5 (−6.5;− 2)
(−19;3)
0.001 (sig.)
 28-TJC 11 (5.5;18.5)
(1;25)
3 (1.5;11)
(0;26)
−4 (−8;0.5)
(−22;6)
0.01 (sig.)
 DAS28(ESR) 5.82 (5.34;6.23)
(3.61;7.57)
3.95 (3.51;5.21)
(3.28;6.19)
−1.62 (−2.61;− 0.51)
(−3.73;0.56)
< 0.001 (sig.)
 GS-synovitis 7 (4.5;9.5)
(2;15)
6 (5;8.5)
(2;10)
−1 (−2;0.75)
(−5;6)
0.1641
 GS-tenosynovitis 2 (2;4)
(0;5)
2.5 (1;3)
(0;4)
0 (−1;1)
(−3;2)
0.506
 PD-synovitis 4 (2.5;7)
(2;15)
3 (1;5)
(0;11)
−1 (−2;0)
(−9;1)
0.0058 (sig.)
 PD-tenosynovitis 2 (1;3)
(0;7)
2.5 (1;3)
(0;5)
0 (−0.75;1)
(−4;1)
0.7732
  1. Clinical and ultrasound (US) parameters at baseline and after 12 months in total population, group of responders and non-responders: *Median (1. quartile; 3. quartile); (min; max), significance level = 0.05; 28-SJC swollen joint count of 28 joints, 28-TJC tender joint count of 28 joints, DAS28(ESR) Disease Activity Score of 28 joints and erythrocyte sedimentation rate (ESR), GS greyscale mode in ultrasound, PD Power Doppler mode in ultrasound